221 related articles for article (PubMed ID: 30190863)
21. Radium and other alpha emitters in prostate cancer.
Sartor O; Sharma D
Transl Androl Urol; 2018 Jun; 7(3):436-444. PubMed ID: 30050802
[No Abstract] [Full Text] [Related]
22. Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors.
Bäck TA; Jennbacken K; Hagberg Thulin M; Lindegren S; Jensen H; Olafsen T; Yazaki PJ; Palm S; Albertsson P; Damber JE; Wu AM; Welén K
EJNMMI Res; 2020 Feb; 10(1):10. PubMed ID: 32048062
[TBL] [Abstract][Full Text] [Related]
23. Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment.
Aris M; Barrio MM
Front Immunol; 2015; 6():46. PubMed ID: 25709607
[TBL] [Abstract][Full Text] [Related]
24. Targeted therapies and immune checkpoint inhibitors in the treatment of metastatic melanoma patients: a guide and update for pathologists.
Kakavand H; Wilmott JS; Long GV; Scolyer RA
Pathology; 2016 Feb; 48(2):194-202. PubMed ID: 27020392
[TBL] [Abstract][Full Text] [Related]
25. Sequencing of New and Old Therapies for Metastatic Melanoma.
Ratterman M; Hallmeyer S; Richards J
Curr Treat Options Oncol; 2016 Oct; 17(10):52. PubMed ID: 27515170
[TBL] [Abstract][Full Text] [Related]
26. Global comparison of targeted alpha vs targeted beta therapy for cancer: In vitro, in vivo and clinical trials.
Marcu L; Bezak E; Allen BJ
Crit Rev Oncol Hematol; 2018 Mar; 123():7-20. PubMed ID: 29482781
[TBL] [Abstract][Full Text] [Related]
27. Monte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy.
Huang CY; Oborn BM; Guatelli S; Allen BJ
Med Phys; 2012 Mar; 39(3):1282-8. PubMed ID: 22380360
[TBL] [Abstract][Full Text] [Related]
28. Targeted Alpha Therapy, an Emerging Class of Cancer Agents: A Review.
; Parker C; Lewington V; Shore N; Kratochwil C; Levy M; Lindén O; Noordzij W; Park J; Saad F
JAMA Oncol; 2018 Dec; 4(12):1765-1772. PubMed ID: 30326033
[TBL] [Abstract][Full Text] [Related]
29. Melanoma therapy via peptide-targeted {alpha}-radiation.
Miao Y; Hylarides M; Fisher DR; Shelton T; Moore H; Wester DW; Fritzberg AR; Winkelmann CT; Hoffman T; Quinn TP
Clin Cancer Res; 2005 Aug; 11(15):5616-21. PubMed ID: 16061880
[TBL] [Abstract][Full Text] [Related]
30. High-linear energy transfer (LET) alpha versus low-LET beta emitters in radioimmunotherapy of solid tumors: therapeutic efficacy and dose-limiting toxicity of 213Bi- versus 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model.
Behr TM; Béhé M; Stabin MG; Wehrmann E; Apostolidis C; Molinet R; Strutz F; Fayyazi A; Wieland E; Gratz S; Koch L; Goldenberg DM; Becker W
Cancer Res; 1999 Jun; 59(11):2635-43. PubMed ID: 10363986
[TBL] [Abstract][Full Text] [Related]
31. The rapidly evolving therapies for advanced melanoma--Towards immunotherapy, molecular targeted therapy, and beyond.
Zhu Z; Liu W; Gotlieb V
Crit Rev Oncol Hematol; 2016 Mar; 99():91-9. PubMed ID: 26708040
[TBL] [Abstract][Full Text] [Related]
32. Radioimmunotherapy with α-particle-emitting radionuclides.
Seidl C
Immunotherapy; 2014; 6(4):431-58. PubMed ID: 24815783
[TBL] [Abstract][Full Text] [Related]
33. Intralesional immunotherapy as a strategy to treat melanoma.
Nouri N; Garbe C
Expert Opin Biol Ther; 2016; 16(5):619-26. PubMed ID: 26898656
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of targeted alpha therapy with
Królicki L; Bruchertseifer F; Kunikowska J; Koziara H; Królicki B; Jakuciński M; Pawlak D; Apostolidis C; Mirzadeh S; Rola R; Merlo A; Morgenstern A
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):614-622. PubMed ID: 30498897
[TBL] [Abstract][Full Text] [Related]
35. A comparative evaluation of Ac225 vs Bi213 as therapeutic radioisotopes for targeted alpha therapy for cancer.
Allen BJ
Australas Phys Eng Sci Med; 2017 Jun; 40(2):369-376. PubMed ID: 28342027
[TBL] [Abstract][Full Text] [Related]
36. Overcoming resistance to targeted therapy with immunotherapy and combination therapy for metastatic melanoma.
Keller HR; Zhang X; Li L; Schaider H; Wells JW
Oncotarget; 2017 Sep; 8(43):75675-75686. PubMed ID: 29088901
[TBL] [Abstract][Full Text] [Related]
37. Kinase inhibitors and immune check-point blockade for the treatment of metastatic melanoma and advanced cancer: synergistic or antagonistic?
Luke JJ; Ott PA
Expert Opin Pharmacother; 2013 Dec; 14(18):2457-62. PubMed ID: 24138302
[TBL] [Abstract][Full Text] [Related]
38. Radioimmunoconjugates for targeted alpha therapy of malignant melanoma.
Abbas Rizvi SM; Sarkar S; Goozee G; Allen BJ
Melanoma Res; 2000 Jun; 10(3):281-9. PubMed ID: 10890383
[TBL] [Abstract][Full Text] [Related]
39. Developments in Intralesional Therapy for Metastatic Melanoma.
Sloot S; Rashid OM; Sarnaik AA; Zager JS
Cancer Control; 2016 Jan; 23(1):12-20. PubMed ID: 27009452
[TBL] [Abstract][Full Text] [Related]
40. Synergy of molecular targeted approaches and immunotherapy in melanoma: preclinical basis and clinical perspectives.
Sanlorenzo M; Vujic I; Moy A; Quaglino P; Fierro MT; Gammaitoni L; Carnevale-Schianca F; Aglietta M; Sangiolo D
Expert Opin Biol Ther; 2015; 15(10):1491-500. PubMed ID: 26206099
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
